Bcl-2 inhibitor-based therapy is expected to be an effective salvage therapy for relapsed and refractory APL harboring RARA-LBD region mutation, which is worthy of further prospective studies. The gene discussed is BCL2; the disease is acute promyelocytic leukemia.